GlassScriptPhysician profile
Yanet Rivas
NPI 1285281790
$14,819.33
in general payments reported to CMS, 2019-2025
45 companies · $4,022 in 2025
The $4,022 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,351 · 2022: $2,174 · 2023: $2,835 · 2024: $4,437 · 2025: $4,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,294.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,326.66 | 2021-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $2,082.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,208.73 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,151.42 | 2021-2025 | Farxiga, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $768.59 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $596.11 | 2021-2025 | |
| Intra-Sana Laboratories | $590.34 | 2024-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Pfizer INC. | $542.49 | 2021-2025 | |
| Ardelyx, INC. | $445.17 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.44 | 2021-2025 | Ofev, Jardiance, Spiriva Respimat |
| Abbvie INC. | $386.01 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $352.72 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.24 | 2021-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $275.88 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $241.83 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $233.86 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $224.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $197.86 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $192.36 | 2024-2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $155.03 | 2023-2024 | Edarbi, Edarbi, Edarbyclor |
| E.R. Squibb & Sons, L.L.C. | $146.96 | 2021-2024 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $141.41 | 2021-2023 | |
| Astellas Pharma US INC | $112.89 | 2024-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $88.49 | 2022-2025 | Quviviq, Quviviq |
| Xeris Pharmaceuticals, INC. | $81.49 | 2025 | Recorlev |
| Sanofi-Aventis U.S. LLC | $72.85 | 2021-2024 | |
| Althera Pharmaceuticals LLC | $58.16 | 2021-2022 | |
| Argenx US, INC. | $43.80 | 2025 | Vyvgart Hytrulo |
| Paratek Pharmaceuticals, INC. | $43.18 | 2021 | |
| Lundbeck LLC | $37.45 | 2025 | Rexulti |
| Mylan Specialty L.P. | $35.01 | 2022 | |
| Ironwood Pharmaceuticals, INC | $28.28 | 2022-2023 | Linzess |
| Allergan, INC. | $25.00 | 2021 | |
| Inspire Medical Systems, INC. | $24.99 | 2025 | Inspire |
| Acadia Pharmaceuticals INC | $24.75 | 2023 | Nuplazid |
| Phathom Pharmaceuticals, INC. | $20.60 | 2025 | Voquezna |
| Lexicon Pharmaceuticals, INC. | $18.18 | 2023 | Inpefa |
| Hikma Pharmaceuticals USA | $16.93 | 2023 | Mitigare, Ryaltris, Kloxxado |
| Biohaven Pharmaceuticals, INC. | $16.07 | 2021 | |
| Redhill Biopharma INC. | $15.95 | 2025 | Talicia |
| Currax Pharmaceuticals LLC | $15.86 | 2025 | Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Biogen, INC. | $15.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.44 | 2025 | Zoryve |
| Almatica Pharma LLC | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanet Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.